Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome (BEAUTY-II)
A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent
Sponsor: Chonnam National University Hospital
Listed as NCT02446730, this PHASE4 trial focuses on Cardiac Death and Cerebrovascular Accident and remains ongoing. Sponsored by Chonnam National University Hospital, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE4
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chonnam National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .